Core Viewpoint - In 2025, the company achieved a revenue of 29.598 billion yuan, a year-on-year increase of 3.2%, while the net profit attributable to shareholders decreased by 2.6% to 2.936 billion yuan, primarily due to a slight decline in gross margin, decreased net financing income, and an increase in the tax rate [1] Revenue and Profit Performance - The company's revenue for 2025 was 29.598 billion yuan, reflecting a 3.2% year-on-year growth, while the net profit attributable to shareholders was 2.936 billion yuan, down 2.6% year-on-year [1] - The decline in net profit was attributed to a slight drop in gross margin, a decrease in net financing income, and an increase in the tax rate [1] Product Category Performance - In 2025, revenue from shoes, apparel, accessories, and equipment was 14.651 billion, 12.327 billion, 2.621 billion, and 0.0 billion yuan respectively, with year-on-year growth rates of 2.4%, 2.3%, and 12.7% [1] - The retail revenue share for running, sports leisure, basketball, and cross-training categories was 31%, 28%, 17%, and 16% respectively, with year-on-year changes of +10%, -9%, -19%, and +5% [1] Channel Performance - Direct sales revenue decreased by 3.3% to 6.655 billion yuan in 2025, with 1,238 direct stores, net closing of 59 stores [2] - Wholesale revenue increased by 6.3% to 13.773 billion yuan, with 4,853 wholesale stores, net opening of 33 stores [2] - E-commerce revenue grew by 5.3% to 8.743 billion yuan, with a year-on-year increase in e-commerce retail revenue in the mid-single digits [2] Profitability and Cost Management - The gross margin for 2025 was 49.0%, down 0.4 percentage points year-on-year, mainly due to a decrease in the proportion of direct sales revenue and increased discounts [3] - The selling expense ratio was 31.0%, down 1.0 percentage points year-on-year, while the management expense ratio increased to 5.5% [3] - The operating profit margin improved by 0.3 percentage points to 13.2%, but the net profit margin decreased by 0.6 percentage points to 9.9% due to lower financing income and increased tax rates [3] Inventory and Cash Flow - As of the end of 2025, the inventory amount was 2.694 billion yuan, a year-on-year increase of 3.7%, with inventory turnover days remaining stable at 64 days [3] - The net cash flow from operating activities was 4.852 billion yuan, a year-on-year decrease of 7.9% [3] Future Outlook - The company is expected to achieve positive year-on-year growth in retail revenue from January to February 2026, with a forecasted high single-digit growth in annual revenue [4] - The estimated EPS for 2026-2028 is projected to be 1.16, 1.26, and 1.38 yuan, with corresponding PE ratios of 15.0, 13.8, and 12.6 times [4]

Core Viewpoint - Kailaiying (002821.SZ) reported a total operating revenue of 6.67 billion yuan for the year 2025, reflecting a year-on-year growth of 14.91% and a constant currency growth of 16.78% [1] Financial Performance - The company achieved a revenue of 2.04 billion yuan in the fourth quarter, which represents a quarter-on-quarter increase of 41.53% and a year-on-year increase of 22.59%, with a constant currency growth of 30.84% [1] - The net profit attributable to shareholders reached 1.13 billion yuan, marking a year-on-year increase of 19.35% [1] - Adjusted net profit was reported at 1.25 billion yuan, showing a significant year-on-year growth of 56.09% [1] Shareholder Returns - The company declared a cash dividend of 13 yuan for every 10 shares to all shareholders [1]

Core Viewpoint - In 2025, China Merchants Bank reported a slight increase in revenue and net profit, indicating a stabilization in financial performance despite challenges in non-interest income and a decline in return on equity [1][2]. Financial Performance - In 2025, the company achieved operating revenue of 337.53 billion yuan, a year-on-year increase of 0.01%, with net profit attributable to shareholders reaching 150.18 billion yuan, up 1.21% [1]. - The annualized weighted ROE was 13.44%, a decrease of 1.05 percentage points year-on-year [1]. Revenue Composition - Net interest income was 215.59 billion yuan, growing by 2.04% and accounting for 63.87% of total revenue [1]. - Non-interest income fell to 121.94 billion yuan, down 3.38%, with its share of total revenue decreasing by 0.21 percentage points compared to the first three quarters of 2025 [1]. Asset Growth - By the end of 2025, the bank's interest-earning assets totaled 12.68 trillion yuan, a year-on-year increase of 7.6% [2]. - Loans, financial investments, and interbank assets grew by 5.6%, 12.6%, and 7.3% respectively, with corporate loans and retail loans increasing by 12.3% and 2.1% [2]. Net Interest Margin - The net interest margin remained stable at 1.87% in 2025 [2]. - The yield on interest-earning assets was 3.04%, while the cost of interest-bearing liabilities was 1.26%, reflecting a slight decrease in both metrics compared to the previous quarter [2]. Non-Interest Income - Non-interest income decreased by 3.38%, but the decline rate narrowed by 0.84 percentage points [3]. - Net fee and commission income rose to 75.26 billion yuan, up 4.39%, driven by a 21.39% increase in wealth management fees [3]. Asset Quality - The non-performing loan ratio stood at 0.94%, unchanged from the previous quarter, indicating strong asset quality [3]. - The coverage ratio for provisions decreased by 14.1 percentage points to 391.8%, while the loan provision ratio fell by 16 basis points to 3.68% [3]. Profit Forecast and Valuation - The bank's operating efficiency is expected to improve steadily, with projected net profit growth rates of 1.44%, 3.21%, and 5.04% for 2026-2028 [3].

Core Viewpoint - China Galaxy (601881.SH) reported a strong financial performance for the year 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company achieved an operating revenue of 28.302 billion yuan, representing a year-on-year increase of 24.34% [1] - The net profit attributable to shareholders reached 12.520 billion yuan, reflecting a year-on-year growth of 24.81% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.522 billion yuan, marking a year-on-year increase of 25.28% [1] Dividend Announcement - The company proposed a dividend of 2.25 yuan per share to all shareholders [1]

Core Viewpoint - The company is expected to achieve strong profit growth in 2026, driven by its leading commercialization capabilities in mainland China and a robust pipeline of new products and biosimilars, alongside an accelerated global expansion strategy [1][2] Group 1: Financial Performance - In 2025, the company's continuing operations revenue grew by 10.3% year-on-year, aligning with previous guidance [1] - Revenue from innovative products increased by 26%, contributing 48% to total revenue, primarily driven by key new products such as PD-L1, long-acting white blood cell enhancers, Bevacizumab, Trastuzumab, Pertuzumab, and seven-factor products [1] - The oncology and liver disease/cardiovascular metabolism sectors recorded revenue growth of 23% and 19%, respectively, due to rapid iteration of new products [1] - Adjusted net profit saw a significant increase of 31.4% due to improvements in gross margin and operating expense ratios [1] Group 2: Product Pipeline and Innovation - The company anticipates nearly 20 new products/new indications to be approved between 2026 and 2028, with over 40 new products expected by 2028, including potential first-in-class CLDN18.2 ADC and best-in-class CD3/EpCAM bispecific antibodies [2] - Recent acquisitions of Lixin and Hejiya are expected to rapidly support the company's pipeline iteration, with multiple single/double antibodies, ADCs, and small nucleic acid drugs expected to yield proof of concept or Phase I data in 2026 [2] - The company is evolving from a local new drug development and commercialization entity into a global comprehensive pharmaceutical innovation platform through open innovation ecosystems, including external licensing, acquisitions, and strategic collaborations [2] Group 3: Valuation and Target Price - The target price has been adjusted downward based on the 2025 performance, reflecting a more cautious outlook on BD collaboration revenue recognition and existing generic drug income [2] - The DCF target price is set at HKD 7.7, corresponding to 36 times/1.1 times the 2026 price-to-earnings ratio/PEG based on core profits, while maintaining a buy rating [2]

Core Viewpoint - China Biopharmaceutical reported a 10.3% year-on-year revenue growth to 31.83 billion yuan in 2025, with innovative product revenue increasing by 26.2% to 1.52 billion yuan, accounting for 47.8% of total revenue [1] Group 1: Financial Performance - The adjusted net profit attributable to shareholders grew by 31.4% year-on-year to 4.54 billion yuan, and even excluding the dividend from Sinovac Biotech, the adjusted net profit still increased by 15% [1] - The company's 2025 revenue was 7.4% lower than the analysts' expectations and 3.9% lower than Bloomberg consensus, while the adjusted net profit fell short by 27.5% and 9.0% respectively, primarily due to the milestone payment of 300 million USD from Merck not being accounted for as expected [1] Group 2: Innovation and Product Pipeline - In 2025, the company achieved approvals for four innovative products, including the world's first CDK2/4/6 inhibitor, Kimosir, and the first high-selectivity HER2 TKI, Zongaitini [2] - The company has a large pipeline of innovative drugs, with 39 in clinical stages in the oncology field, including several assets with global first-in-class or best-in-class potential [2] - The management aims to obtain approvals for nearly 20 innovative products and new indications between 2026 and 2028 [2] Group 3: Strategic Collaborations and Acquisitions - In February 2026, the company entered a global exclusive licensing agreement with Sanofi for 135 million USD upfront, along with milestone payments and sales royalties for the global development and commercialization rights of Roflumilast [3] - The company completed two significant acquisitions: a full acquisition of Lixin Pharmaceutical for up to 950 million USD in July 2025 and a 1.2 billion yuan acquisition of Hejiya in January 2026 [3] - The management indicated that external licensing will be a core objective for future business development, with expectations for continued successful licensing agreements [3] Group 4: Future Outlook - The company is set to disclose multiple important clinical data in 2026, including Phase I data for various innovative treatments at major conferences [3] - The target price based on DCF has been adjusted from 9.40 HKD to 8.70 HKD, reflecting a downward revision in expectations for non-business development revenue [4] - Revenue growth projections for 2026E/27E/28E are 13.5%/7.1%/9.2%, with adjusted net profit growth of 5.4%/8.3%/10.5% [4]

Core Viewpoints - China Biopharmaceutical reported a total revenue of 31.83 billion yuan for the year 2025, representing a year-on-year growth of 10.3% [1][2] - Adjusted net profit attributable to shareholders reached 4.541 billion yuan, a significant increase of 31.4% year-on-year; core net profit growth reached 15% when excluding factors like the Sinovac dividend [1][2] - The company’s innovative business showed strong performance, with revenue from innovative products growing by 26.2% year-on-year [1][2] - The internationalization strategy yielded significant results, highlighted by a $1.53 billion exclusive licensing agreement for the global FIC drug Rovaxitinib with Sanofi, marking the largest transaction in China's transplant field [1] Financial Performance - The company achieved a total revenue of 31.83 billion yuan in 2025, with a 10.3% increase compared to the previous year [1][2] - The adjusted net profit attributable to shareholders was 4.541 billion yuan, reflecting a 31.4% year-on-year growth [1][2] - The core product sales continued to grow, contributing to a robust financial position with ample cash reserves [1] Innovation and Product Development - The innovative business became the core growth engine, with innovative product revenue increasing by 26.2% year-on-year [2] - Anlotinib, a key product, benefited from the approval of three new first-line indications in 2025, leading to significant sales growth [2] - The company is focusing on several key clinical data releases in 2026, including results for LM-302 in first-line gastric cancer and TQB6411 in late-stage malignancies [8] Research and Development - The company is accelerating clinical progress in oncology, with multiple products showing FIC/BIC potential [3][4] - The small RNA business is developing a long-acting siRNA pipeline, with Kylo-11 showing significant potential in the cardiovascular field [4][5] - The company has established a comprehensive small RNA technology platform, laying the foundation for future product development and commercialization [5] Future Outlook - The company expects to achieve revenues of 35.782 billion yuan, 40.899 billion yuan, and 47.075 billion yuan from 2026 to 2028, with corresponding net profits of 3.591 billion yuan, 4.164 billion yuan, and 4.808 billion yuan [9] - The company maintains a "buy" rating based on its growth prospects and expected financial performance [9]

Core Viewpoint - The company reported a decline in revenue and net profit for 2025, primarily due to reduced income from supporting services and real estate, while toll revenue showed resilience and growth in core operations [1][2]. Revenue Performance - The company achieved approximately RMB 20.289 billion in revenue for 2025, a year-on-year decrease of about 12.54%, with core revenue (excluding construction income) at approximately RMB 12.134 billion, down about 1.61% [1][2]. - Toll revenue reached approximately RMB 9.555 billion, reflecting a year-on-year growth of about 0.29%, indicating the resilience of the main business [2]. Traffic Volume and Toll Income - Traffic volumes for key routes such as the Shanghai-Nanjing Expressway and Wuxi Ring Taihu Road increased by 1.84% and 4.50% respectively, contributing to a growth in toll income for several routes [2]. - The company experienced a decline in toll income for some routes due to construction, but parallel routes benefited from traffic diversion, leading to overall growth in toll revenue [2]. Cost Management and Profitability - The company's operating costs totaled RMB 14.188 billion, down approximately 17.03%, with core operating costs at RMB 6.032 billion, a decrease of about 3.25% [3]. - Management and financial expenses decreased by 5.54% and 13.01% respectively, reflecting improved operational efficiency and cost control [3]. Investment Income and Profit Forecast - Investment income for 2025 was RMB 1.255 billion, a decline of 29.52%, primarily due to reduced dividends from Jiangsu Bank and lower contributions from joint ventures [3]. - The company has revised its profit forecasts downward for 2026-2027, with expected net profits of RMB 4.709 billion, RMB 4.734 billion, and RMB 4.820 billion for 2026E-2028E, respectively [4]. Rating and Valuation - Despite the challenges, the company maintains a "Buy" rating, as its toll road business shows steady growth compared to peers, with a projected PE ratio of 13 for 2026-2028 [4].

Group 1 - The company, China Eastern Airlines (600115.SH), announced a share buyback plan through centralized bidding, with a total amount not less than 500 million yuan and not exceeding 1 billion yuan (excluding the principal) [1] - The maximum buyback price is set at 5 yuan per share, with an estimated buyback quantity of 100 million to 200 million shares, representing approximately 0.45% to 0.91% of the total share capital [1] - The funds for the buyback will come from the company's self-raised funds, and the implementation period is within 12 months after the approval by the shareholders' meeting [1]

Core Viewpoint - The company reported a significant increase in net revenue for the fiscal year ending December 31, 2025, driven by improved performance in its entertainment and hotel operations [1] Financial Performance - The net revenue for the year was HKD 40.24 billion, representing an 11.2% year-on-year increase [1] - The profit attributable to equity holders of the company was HKD 1.06 billion, a turnaround from a loss of HKD 780 million in the previous year [1] - Basic earnings per share attributable to equity holders were HKD 0.50 [1] Future Outlook - The company plans to continue focusing on new initiatives, including the luxury hotel project REM at City of Dreams, expected to open in the second half of 2026 [1] - Upgrades are being made to retail and dining facilities at City of Dreams to meet evolving guest expectations, ensuring that offerings remain high-quality, innovative, and luxurious [1]